Publication:
Mitoxantrone as a TRAIL-sensitizing agent for glioblastoma multiforme

dc.contributor.coauthorAyhan, Ceyda Açılan
dc.contributor.departmentDepartment of Molecular Biology and Genetics
dc.contributor.departmentGraduate School of Health Sciences
dc.contributor.departmentGraduate School of Sciences and Engineering
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorCingöz, Ahmet
dc.contributor.kuauthorKaya, Ezgi
dc.contributor.kuauthorKazancıoğlu, Selena
dc.contributor.kuauthorLack, Nathan Alan
dc.contributor.kuauthorÖnder, Tuğba Bağcı
dc.contributor.kuauthorŞenbabaoğlu, Fatih
dc.contributor.schoolcollegeinstituteCollege of Sciences
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF HEALTH SCIENCES
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF SCIENCES AND ENGINEERING
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:05:29Z
dc.date.issued2016
dc.description.abstractBackground: Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) has tremendous promise in treating various forms of cancers. However, many cancer cells exhibit or develop resistance to TRAIL. Interestingly, many studies have identified several secondary agents that can overcome TRAIL resistance. To expand on these studies, we conducted an extensive drug-re-profiling screen to identify FDA-approved compounds that can be used clinically as TRAIL-sensitizing agents in a very malignant type of brain cancer, glioblastoma multiforme (GBM). Material and Methods: GBM cell lines U87MG, U373 and non-malignant cell lines BJ fibroblasts and Normal Human Astrocytes were used in in vitro experiments. 1,200 FDA approved drugs containing library was screened as single agents (5 uM) and/or TRAIL (25 ng/ml) in U87MG and U87MGR50. Cell viability was detected by an ATP-based assay after 24−48 hours. Chosen lead, Mitoxantrone was further studied by cell viability assays, proliferation by live cell imaging, apoptotic gene expression levels by qRT-PCR and death receptor and apoptotic protein expression levels by Western Blot. Results: Using selected isogenic GBM cell pairs with differential levels of TRAIL sensitivity, we revealed 26 TRAIL-sensitizing compounds, 13 of which were effective as single agents. Cardiac glycosides constituted a large group of TRAIL-sensitizing compounds, and they were also effective on GBM cells as single agents. We then explored a second class of TRAIL-sensitizing drugs, which were enhancers of TRAIL response without any effect on their own. One such drug, Mitoxantrone, a DNA-damaging agent, did not cause toxicity to non-malignant cells at the doses that synergized with TRAIL on tumor cells. We investigated the downstream changes in apoptosis pathway components upon Mitoxantrone treatment, and observed that Death Receptors (DR4 and DR5) expression was upregulated, and pro-apoptotic and anti-apoptotic gene expression patterns were altered in favor of apoptosis. Conclusions: Together, our results suggest that combination of Mitoxantrone and TRAIL can be a promising therapeutic approach for GBM patients.
dc.description.indexedbyWOS
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume69
dc.identifier.doi10.1016/S0959-8049(16)32835-0
dc.identifier.eissn1879-0852
dc.identifier.issn0959-8049
dc.identifier.quartileQ1
dc.identifier.urihttps://doi.org/10.1016/S0959-8049(16)32835-0
dc.identifier.urihttps://hdl.handle.net/20.500.14288/8819
dc.identifier.wos390503500230
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofEuropean Journal of Cancer
dc.subjectOncology
dc.titleMitoxantrone as a TRAIL-sensitizing agent for glioblastoma multiforme
dc.typeMeeting Abstract
dspace.entity.typePublication
local.contributor.kuauthorŞenbabaoğlu, Fatih
local.contributor.kuauthorCingöz, Ahmet
local.contributor.kuauthorKaya, Ezgi
local.contributor.kuauthorKazancıoğlu, Selena
local.contributor.kuauthorLack, Nathan Alan
local.contributor.kuauthorÖnder, Tuğba Bağcı
local.publication.orgunit1GRADUATE SCHOOL OF SCIENCES AND ENGINEERING
local.publication.orgunit1GRADUATE SCHOOL OF HEALTH SCIENCES
local.publication.orgunit1College of Sciences
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2Department of Molecular Biology and Genetics
local.publication.orgunit2School of Medicine
local.publication.orgunit2Graduate School of Sciences and Engineering
local.publication.orgunit2Graduate School of Health Sciences
relation.isOrgUnitOfPublicationaee2d329-aabe-4b58-ba67-09dbf8575547
relation.isOrgUnitOfPublication2f870f28-12c9-4b28-9465-b91a69c1d48c
relation.isOrgUnitOfPublication3fc31c89-e803-4eb1-af6b-6258bc42c3d8
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryaee2d329-aabe-4b58-ba67-09dbf8575547
relation.isParentOrgUnitOfPublicationaf0395b0-7219-4165-a909-7016fa30932d
relation.isParentOrgUnitOfPublication4c75e0a5-ca7f-4443-bd78-1b473d4f6743
relation.isParentOrgUnitOfPublication434c9663-2b11-4e66-9399-c863e2ebae43
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscoveryaf0395b0-7219-4165-a909-7016fa30932d

Files